Critical Contrast: ImmuCell (NASDAQ:ICCC) & Celldex Therapeutics (NASDAQ:CLDX)

ImmuCell (NASDAQ:ICCC) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Earnings & Valuation

This table compares ImmuCell and Celldex Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell $10.99 million 4.30 -$2.32 million N/A N/A
Celldex Therapeutics $9.54 million 3.64 -$151.18 million ($6.82) -0.37

ImmuCell has higher revenue and earnings than Celldex Therapeutics.

Insider and Institutional Ownership

22.6% of ImmuCell shares are held by institutional investors. Comparatively, 21.3% of Celldex Therapeutics shares are held by institutional investors. 17.7% of ImmuCell shares are held by company insiders. Comparatively, 2.4% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for ImmuCell and Celldex Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell 0 0 0 0 N/A
Celldex Therapeutics 0 2 2 0 2.50

Celldex Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 653.97%. Given Celldex Therapeutics’ higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than ImmuCell.

Profitability

This table compares ImmuCell and Celldex Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmuCell -15.62% -5.71% -4.00%
Celldex Therapeutics -729.59% -45.09% -34.19%

Volatility & Risk

ImmuCell has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 3.95, indicating that its stock price is 295% more volatile than the S&P 500.

Summary

ImmuCell beats Celldex Therapeutics on 8 of the 11 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.